Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 75%
filed 2026-08-24
The Company suspended and is terminating its at-the-market (ATM) sales agreement with Chaince Securities, LLC under which it had sold 25,606,595 Ordinary Shares for approximately $2.3 million in gross proceeds since July 2026. While the termination itself is administrative, the disclosure documents the completion of a dilutive equity issuance under an ATM offering program, which materially affects shareholder equity and voting power. The suspension and termination of the agreement is the operative event being disclosed.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-08-24
Item 1.01
Change Agents Corporation amended its Equity Purchase Agreement with Hudson Global Ventures, LLC on August 21, 2026, establishing a $10,000,000 equity line of credit whereby the Company can require the Investor to purchase common stock at $0.20 per share, subject to an Exchange Cap limiting issuances to 19.99% of outstanding shares pending stockholder approval. This unregistered equity issuance is material and dilutive to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-24
Item 1.01
Greenland Mines entered into an at-the-market (ATM) sales agreement with A.G.P./Alliance Global Partners on August 24, 2026, authorizing the sale of up to $50,000,000 in common stock shares. This is a classic dilutive equity issuance under Rule 415(a)(4), where the company may sell registered shares at market prices through a sales agent. The filing explicitly describes this as an "ATM Offering" and notes the company has no obligation to sell but may do so from time to time, making this a material capital-raising activity that would dilute existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-24
Item 1.01
The Company entered into two registered direct offerings on August 18 and August 20, 2026, selling 340,000 shares and 451,250 shares of common stock respectively, plus pre-funded warrants to purchase 260,000 and 1,111,250 additional shares, for aggregate gross proceeds of approximately $6.8 million. This is a material dilutive equity issuance that raises capital through the sale of common stock and immediately-exercisable warrants, typical of a PIPE-like registered direct offering structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
The Company issued 773,361 shares of common stock (220,264 + 553,097) to Lind Global Asset Management in satisfaction of conversion obligations under senior secured convertible promissory notes totaling $9.9 million in principal. The disclosure explicitly states reliance on Section 3(a)(9), Section 4(a)(2), and Rule 506 of Regulation D—all exemptions from registration under the Securities Act—and notes the issuance was to an existing securityholder without general solicitation. This is a classic dilutive equity issuance by a small-cap biotech company to a financial investor, material to shareholders' ownership and voting interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
The filing discloses two equity issuances: (1) an unregistered sale of 107,920 shares to Yorkville under a Standby Equity Purchase Agreement for $851,194 (Item 3.02), and (2) a registered direct offering of 307,692 shares for approximately $2.0 million (Item 8.01/press release). Both represent dilutive equity issuances to raise capital. Item 3.02 explicitly covers unregistered sales under Section 4(a)(2) and Regulation D, which is the core dilutive_issuance category. The registered offering, while technically registered, is still a material capital raise that dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-24
Jupiter Neurosciences completed a registered direct offering on August 24, 2026, issuing 307,692 shares of common stock at $6.50 per share for approximately $2.0 million in gross proceeds. The filing explicitly discloses this equity issuance under Item 8.01 and notes the company's reliance on the offering proceeds to maintain compliance with Nasdaq's $2.5 million stockholders' equity listing requirement, indicating material capital-raising activity and dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-08-24
Item 1.01
Skye Bioscience entered into a Securities Purchase Agreement with Redmile Biopharma Investments III, L.P. on August 21, 2026, to sell up to $22,000,000 of ELOC Shares (common and non-voting convertible shares) plus a warrant to purchase additional shares valued at $5,000,000, pursuant to Section 4(a)(2) exemption. The transaction includes a 19.99% cap on outstanding shares (subject to stockholder approval for excess) and a 9.99% beneficial ownership limitation for the investor, representing significant equity dilution for existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
The filing discloses multiple unregistered sales of equity securities by Brookfield Real Estate Income Trust Inc. during August 2026, including 115,918 Class I shares to the Adviser as management fees, 24,886 Class C shares to a feeder vehicle, 6,517 Class I shares via distribution reinvestment to a feeder vehicle, 124,331 Class I shares via distribution reinvestment to Brookfield affiliates, and 26,633 Class E shares to Brookfield employees, totaling approximately $3.3 million in aggregate consideration. These private placements under Section 4(a)(2) and Regulation S/D represent dilutive equity issuances that would materially affect investor assessment of share ownership and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
Blue Owl Credit Income Corp. completed an unregistered private placement of 251,525 shares of Class I common stock to feeder vehicles for approximately $2.3 million, exempt under Section 4(a)(2) and Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
Blue Owl Technology Income Corp. completed an unregistered private placement of 136,101 shares of Class I common stock to feeder vehicles for $1,316,100, exempt under Section 4(a)(2) and Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
The filing discloses an unregistered sale of 272,642 common shares for $7,126,860 pursuant to Section 4(a)(2) and Regulation D/S under the Securities Act. This is a classic dilutive issuance of equity securities outside registered offerings, which materially affects existing shareholders' ownership percentages and is a key disclosure for investors assessing capital structure and dilution risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
Golub Capital Private Income Fund S issued 2,068 common shares of beneficial interest for $50,000 in consideration pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions, representing an unregistered equity issuance outside registered offerings.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
Golub Capital Private Income Fund I issued 53,881 common shares of beneficial interest for $1,305,000 as of August 1, 2026, pursuant to subscription agreements and exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-21
Item 8.01
The Company increased the maximum aggregate offering price under an at-the-market (ATM) sales agreement with Benchmark and StoneX by $2,270,000 in additional common stock, following approximately $2,228,999 already sold under the same agreement. This is a dilutive equity issuance disclosed under Item 8.01, representing a material capital-raising activity that would affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-08-20
EX-99.1
Nebius Group announced pricing of a $5.0 billion private offering of convertible senior notes (upsized from $4.5 billion) to qualified institutional buyers under Rule 144A, with settlement expected August 24, 2026. The convertible notes are dilutive securities that will result in issuance of approximately 15.8 million Class A shares through concurrent exchange transactions with existing convertible noteholders, plus additional shares upon conversion of the new notes. This is a material capital-raising event typical of dilutive issuances at growth-stage technology companies.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 3.02
Stone Point Credit Income Fund issued 113,049.904 common shares at NAV of $24.6493 for an aggregate offering price of $2,876,601 pursuant to subscription agreements with accredited investors. The disclosure explicitly states the sale is exempt from Securities Act registration under Section 4(a)(2) and Regulation D Rule 506, which is the hallmark of a private placement. This is a material unregistered equity issuance that dilutes existing shareholders and represents a significant capital raise for the Fund.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 1.01
Evolution Petroleum completed a registered public offering of 3,700,000 shares of common stock at $3.25 per share on August 20, 2026, with underwriters exercising their 30-day option for an additional 555,000 shares, generating net proceeds of approximately $12.4 million. This dilutive equity issuance raises capital for the company while diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-08-20
Item 1.01
Edesa Biotech entered into an underwriting agreement on August 19, 2026 for a registered public offering of 3,870,500 common shares with warrants and 675,000 pre-funded warrants, raising approximately $25 million in gross proceeds ($23.1 million net). The offering includes an underwriter option for an additional 681,825 shares and represents a material dilutive equity issuance typical of clinical-stage biotech capital raises.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-20
The 6-K discloses a private placement of 5,000,000 Class A ordinary shares at US$0.80 per share for aggregate gross proceeds of US$4,000,000, entered into on August 14, 2026. This is an unregistered equity issuance that dilutes existing shareholders and raises capital, fitting the definition of dilutive_issuance. The materiality is clear given the significant share count and capital raised.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-20
EX-99.1
This exhibit announces a registered direct offering of 1.75 million Class A Ordinary Shares at $1.00 per share, generating approximately $1.75 million in gross proceeds. The offering is structured as a registered direct offering under a Form F-3 shelf registration statement, which is a classic dilutive equity issuance. The announcement explicitly states the offering is expected to close on August 20, 2026, and involves institutional investors purchasing shares or pre-funded warrants, making this a material capital-raising event that would dilute existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-20
EX-99.1
QTREX announced pricing of a $10 million registered direct offering of 11,111,111 ordinary shares to institutional investors. This is a registered equity issuance under Form F-3 that will dilute existing shareholders. The announcement of definitive terms, pricing, and expected closing date (August 21, 2026) constitutes a material capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-20
Item 3.02
AB Private Lending Fund completed an unregistered private placement of 40,519 Class I common shares of beneficial interest to feeder vehicles, exempt under Section 4(a)(2) and Regulation S, materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 3.02
Audax Private Credit Fund issued 1,718,450.952 limited liability company interests for $42.2 million on July 1, 2026, to accredited investors and non-U.S. persons pursuant to subscription agreements exempt from Securities Act registration under Section 4(a)(2) and Regulations D/S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-20
Item 1.01
QNB Corp. completed a registered public offering of 1,232,142 shares of common stock at $42.00 per share (including the full exercise of the underwriters' 30-day overallotment option), generating approximately $48.3 million in net proceeds. The offering will be used for balance sheet restructuring, subordinated note redemption, and capital support, and materially dilutes existing shareholders' ownership and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 3.02
Goldman Sachs Private Credit Corp. completed an unregistered sale of equity securities totaling approximately $155.7 million across Class I, S, and D shares pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions to accredited investors and non-U.S. persons.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-20
EZGO Technologies entered into a securities purchase agreement on August 5, 2026, to issue 3,000,000 ordinary shares at US$0.50 per share for aggregate gross proceeds of US$1.5 million in a private investment in public equity (PIPE) transaction. The shares were issued on August 19, 2026, and were offered in reliance on Regulation S exemption from registration. This is a classic dilutive equity issuance that would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 8.01
CleanCore Solutions disclosed a best efforts public offering of approximately 275.8 million shares of common stock, pre-funded warrants, and accompanying warrants to purchase 400 million additional shares. The filing confirms that as of August 20, 2026, the Company had 502.1 million shares outstanding as a result of this issuance. This represents a massive dilutive equity issuance that materially increases the share count and would significantly affect investor assessment of ownership dilution and earnings per share.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 3.02
NorthStrive completed a private placement of 231,750 units to the Sponsor at $10.00 per unit, generating $2,317,500 in gross proceeds, pursuant to Section 4(a)(2) exemption from registration, simultaneously with the IPO closing.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-20
The filing discloses entry into a First Amended and Restated Purchase Agreement granting an investor the right to purchase up to $75 million of unregistered common stock shares at discounted prices (95% or 75% of market price depending on trading status), increased from $25 million under the original agreement. This is a classic equity line of credit (ELOC) arrangement—an unregistered private placement of equity securities with dilutive pricing mechanics. Item 3.02 explicitly incorporates the securities description, confirming this as an unregistered equity issuance event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
The filing discloses a firm commitment underwritten public offering of 3,437,500 shares of common stock at $3.20 per share, generating $11 million in gross proceeds. This is a registered equity issuance under an effective Form S-3 shelf registration statement, representing a material capital raise that dilutes existing shareholders. The press release explicitly states the offering is expected to close on August 21, 2026, and details the use of proceeds for R&D, sales and marketing, and working capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-20
The filing discloses conversion of $3,000,000 in debt into 1,829,268 shares of common stock at $1.64 per share, executed via a Debt Conversion Agreement with Rare Earth Financial, LLC. This is a dilutive equity issuance that increases share count materially. While Item 1.01 frames it as a material definitive agreement and Item 3.02 explicitly addresses unregistered equity sales, the core event is the issuance of equity securities in exchange for debt cancellation, which is a classic dilutive capital transaction.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-20
EX-99.1
This press release announces the completion of a US$4.0 million private placement of 4.0 million ordinary shares at US$1.00 per share—an unregistered equity issuance by a small-cap public company. The transaction is a classic dilutive equity raise: common shares issued in a private placement exempt from Securities Act registration, with no warrants or convertibles. The 160% premium to the prior closing price and the capital infusion are material to investors assessing the company's financial position and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Newton Golf Company entered into a Securities Purchase Agreement on August 14, 2026 for a private placement of common stock with up to $5,000,000 in aggregate proceeds (first tranche of $1,000,000 closed immediately). The shares are unregistered securities sold pursuant to Section 4(a)(2) and Regulation D exemptions to accredited investors. This is a classic dilutive equity issuance disclosed under Item 1.01 and Item 3.02, representing a material capital raise that dilutes existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-08-20
The filing discloses adjustment of warrant exercise prices and share counts following a 45-for-1 share consolidation effected in August 2026. The warrant adjustments—reducing exercise price to $3.80 per share and increasing shares issuable to approximately 3,193,862—reflect anti-dilution provisions triggered by the consolidation and prior offerings in May, July, and August 2026. While the primary event is a technical warrant adjustment rather than a new issuance, the disclosure concerns dilutive equity instruments (warrants) and their adjustment mechanics, which materially affect shareholder dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-20
Item 3.02
Rise Companies Corp. qualified 4,275,000 shares of Class B Common Stock for sale in a continuous offering under Regulation A (Rule 251(d)(3)), with an expected offering period through September 23, 2028. This unregistered equity issuance will dilute existing shareholders and raise capital for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 3.02
The filing discloses unregistered sales of equity securities totaling approximately $33.9 million across two share classes (Class C and Class L) sold on July 1 and August 1, 2026. The sales were exempt from registration under Section 4(a)(2), Regulation S, and Regulation D—classic private placement mechanics. This represents a material dilutive issuance that would affect investor assessment of ownership and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 88%
filed 2026-08-20
Item 3.02
On August 19, 2026, Sadot Group Inc. issued 33,968 common shares at a below-market price to settle an assigned debenture with an existing debt holder, relying on the Section 3(a)(9) exemption. The debt-for-equity conversion resulted in dilution to existing shareholders and triggered anti-dilution adjustments in other debt instruments.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-20
WF International entered into a Share Purchase Agreement on August 19, 2026, to sell and issue 111,333 ordinary shares at $1.50 per share in a registered direct offering, expected to close August 21, 2026. The offering is registered under Form F-3 and will raise approximately $166,999.50 in gross proceeds. This is a registered direct offering of equity securities that dilutes existing shareholders and is material to investor assessment of capital structure and ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 3.02
Monroe Capital issued 1,664,638 shares of common stock at $9.77 per share for an aggregate offering price of $16.3 million pursuant to subscription agreements, exempt from registration under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 3.02
In connection with the exchangeable notes offering, Dynatrace's subsidiary issued warrants to purchase up to 44.7 million shares of common stock, and up to 30.2 million shares of common stock are potentially issuable upon exchange of the notes. The warrant and exchange transactions were issued in a private placement under Rule 144A and Section 4(a)(2), creating potential dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 3.02
Blackstone Private Credit Fund completed an unregistered private placement of 1,339,715 Class I common shares for $31.7 million, conducted pursuant to Section 4(a)(2) and Regulation S exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-20
Item 1.01
Nexalin entered into a securities purchase agreement on August 19, 2026, to issue 2,419,355 shares of common stock at $0.31 per share and common warrants to purchase 1,209,677 additional shares at $0.50 per share in a registered direct offering raising approximately $750,000, plus an any-market purchase agreement (AMPA) for up to $15 million in future share purchases. The company also issued unregistered equity securities including Common Warrants, Pre-Funded Warrants (with $0.001 exercise price), and AMPA Shares to accredited investors pursuant to Regulation D, materially increasing share count and dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 3.02
Barings Private Credit Corp completed an unregistered sale of approximately 5.1 million shares of common stock for $101.5 million pursuant to Section 4(a)(2) and Regulation D/S. This private placement materially increases share count and dilutes existing shareholders' ownership percentages and earnings per share.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Item 3.02
North Haven Net REIT sold an aggregate of 289,618 Class I shares and 5,591 Class F-I shares for approximately $6.15 million in total consideration to a feeder vehicle. The sale was structured as an unregistered offering under Section 4(a)(2) and Regulation D Rule 506, which is the classic structure for dilutive equity issuances. The materiality threshold is clearly met given the substantial dollar amount and share count involved.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-08-19
Item 3.02
ZeroStack issued 3.5 million common shares and pre-funded warrants to purchase 36.2 million additional shares in a private placement to Puple AI Inc. and Blockcat Pte. Ltd. in exchange for $1 billion in MemeCore tokens, representing substantial dilution to existing shareholders and relying on Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-19
Item 8.01
EDAP TMS disclosed the closing of an underwritten public offering of 8,425,000 ADSs at $4.75 per share on August 14, 2026, plus the full exercise of a 30-day greenshoe option for an additional 1,263,750 ADSs expected to close on August 19, 2026, generating approximately $5.6 million in net proceeds. This is a material dilutive equity issuance that increases the share count and raises capital, fitting the dilutive_issuance category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 80%
filed 2026-08-19
Item 1.01
Datavault AI issued 15,000,000 pre-delivery shares and a $25,030,000 convertible promissory note to Streeterville Capital in a private placement, with conversion rights at $1.55 per share and a reinvestment option for up to an additional $25,000,000. The transaction includes a 300,000,000-share reserve for conversion shares and requires Nasdaq stockholder approval, representing substantial dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-19
Item 1.01
XCel Brands entered into an Equity Distribution Agreement with Maxim Group LLC authorizing the sale of up to $10,000,000 of common stock through an at-the-market (ATM) offering on the Nasdaq Capital Market. This is a registered direct offering of equity securities that will dilute existing shareholders and is material to investors assessing the company's capital structure and financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-19
Item 8.01
The filing discloses registration of resale shares pursuant to a Stock Purchase Agreement dated February 11, 2026 between Twist Bioscience and Invenra, with a Registration Rights Agreement governing the resale. This represents a dilutive equity issuance to a third party (Invenra) with contractual resale rights, which is material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →